Department of Pulmonology and Thoracic Oncology and Jessa & Science, Jessa Hospital Hasselt, Belgium; Faculty of Medicine and Life Sciences, LCRC, UHasselt, Diepenbeek, Belgium; Department of Thoracic Oncology, The Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, the Netherlands.
Department of Thoracic and Vascular Surgery, Jessa Hospital Hasselt, Belgium.
Lung Cancer. 2024 Jul;193:107855. doi: 10.1016/j.lungcan.2024.107855. Epub 2024 Jun 14.
The introduction of immune checkpoint inhibitors significantly advanced outcomes in both metastatic and locally advanced non-small cell lung cancer. Despite these advancements, the 5-year survival rate remains suboptimal. Even in early-stage disease a significant portion of patients relapse and die from metastatic progression. The integration of immunotherapy in the management of early-stage NSCLC demonstrated promising results, supported by a plethora of positive clinical trials conducted in recent years. Nonetheless, numerous questions persist. In this manuscript we comprehensively review the currently available data on adjuvant, neoadjuvant, and perioperative treatment strategies. We also address the challenges inherent to these approaches from different stakeholders' perspective.
免疫检查点抑制剂的引入显著改善了转移性和局部晚期非小细胞肺癌患者的预后。尽管取得了这些进展，但 5 年生存率仍不理想。即使在早期疾病中，仍有相当一部分患者因转移进展而复发和死亡。免疫疗法在早期 NSCLC 中的应用已显示出令人鼓舞的结果，这得到了近年来大量阳性临床试验的支持。尽管如此，仍存在许多问题。在本文中，我们全面回顾了辅助、新辅助和围手术期治疗策略的现有数据。我们还从不同利益相关者的角度探讨了这些方法所固有的挑战。
